Skip to main content
Fig. 2 | Addiction Science & Clinical Practice

Fig. 2

From: Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use

Fig. 2

Proportion of participants with HIV and opioid use disorder who initiated clinic-based buprenorphine in each opioid use disorder treatment stage in the Johns Hopkins HIV Clinical Cohort restricted to 4-year follow-up, with retention defined as ≥ 180 days of treatment without a > 7-day gap

Back to article page

Addiction Science & Clinical Practice

ISSN: 1940-0640